TLR4 and Cognitive impairment: Treatment with a GSK-3β inhibitor, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), ameliorated cognitive impairment by reducing TLR4 expression and increasing the expression of junction proteins (claudin1 and claudin5) in endothelial cells of the BBB.